Spots Global Cancer Trial Database for proteasome inhibitor
Every month we try and update this database with for proteasome inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer | NCT00798720 | Carcinoma, Non ... | vorinostat bortezomib | 18 Years - | University of Wisconsin, Madison | |
| Quality of Life in Multiple Myeloma Patients Treated With Bortezomib | NCT01021592 | Multiple Myelom... | bortezomib | 18 Years - | Janssen Korea, Ltd., Korea | |
| Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | NCT02189343 | Multiple Myelom... | ACY-1215 in com... | 18 Years - | Celgene | |
| Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | NCT01658904 | Multiple Myelom... Leukemia, Plasm... | Carfilzomib Melphalan Filgrastim | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT01832727 | Multiple Myelom... | Oprozomib Dexamethasone | 18 Years - | Amgen | |
| Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance | NCT01647165 | Multiple Myelom... | Bortezomib Lenalidomide Dexamethasone | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. | NCT01026701 | Multiple Myelom... | bortezomib | 18 Years - | Janssen Korea, Ltd., Korea | |
| UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment | NCT02499081 | Multiple Myelom... | Ixazomib | 18 Years - 75 Years | University of Arkansas | |
| Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab | NCT02330562 | Malignant Gliom... Glioblastoma | MRZ BEV | 18 Years - | Celgene | |
| Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma | NCT00416208 | Multiple Myelom... | Bortezomib | 61 Years - 75 Years | Janssen-Cilag G.m.b.H | |
| Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy | NCT00038571 | Lymphoma, B-Cel... | PS341 (Bortezom... | 17 Years - | M.D. Anderson Cancer Center | |
| Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | NCT00522392 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib lenalidomide dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma | NCT01572480 | Multiple Myelom... | Carfilzomib Revlimid Dexamethasone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | NCT04096066 | Multiple Myelom... New Diagnosis T... | Carfilzomib Lenalidomide Dexamethasone | 65 Years - | Fondazione EMN Italy Onlus | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | NCT02189343 | Multiple Myelom... | ACY-1215 in com... | 18 Years - | Celgene | |
| MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma | NCT01660997 | Multiple Myelom... | MLN9708 Dexamethasone | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment | NCT02499081 | Multiple Myelom... | Ixazomib | 18 Years - 75 Years | University of Arkansas | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma | NCT02756663 | Multiple Myelom... | panobinostat (c... carfilzomib (in... dexamethasone (... | 18 Years - | Novartis | |
| Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) | NCT02102594 | Myasthenia Grav... Systemic Lupus ... Rheumatoid Arth... | Bortezomib | 18 Years - 75 Years | Charite University, Berlin, Germany | |
| Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone | NCT00522392 | Stage I Multipl... Stage II Multip... Stage III Multi... | bortezomib lenalidomide dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma | NCT03323151 | Mantle-Cell Lym... | Ixazomib Ixazomib Ibrutinib Ibrutinib | 18 Years - | PrECOG, LLC. | |
| Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma | NCT01881789 | Multiple Myelom... | Oprozomib Lenalidomide Dexamethasone Cyclophosphamid... | 18 Years - | Amgen | |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | NCT05730036 | Relapsed Refrac... | Linvoseltamab Elotuzumab Pomalidomide Dexamethasone | 18 Years - | Regeneron Pharmaceuticals | |
| Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | NCT03643276 | Acute Lymphobla... | Blinatumomab Bortezomib Cyclophosphamid... Cytarabine Daunorubicin Myocet Dexamethasone Doxorubicin Etoposide Fludarabine Pho... Ifosfamide 6-Mercaptopurin... Methotrexate Pegaspargase Prednisolone Tioguanin Vincristine Vindesine Erwinase | - 17 Years | University Hospital Schleswig-Holstein | |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | NCT05730036 | Relapsed Refrac... | Linvoseltamab Elotuzumab Pomalidomide Dexamethasone | 18 Years - | Regeneron Pharmaceuticals | |
| Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant | NCT05271630 | Multiple Myelom... | Autologous Stem... Immunomodulator... Proteasome Inhi... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. | NCT00440479 | Multiple Myelom... Hematological N... | Bortezomib | 18 Years - | Janssen-Cilag B.V. | |
| Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma | NCT04933539 | Multiple Myelom... | Dexamethasone Carfilzomib Daratumumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | NCT01658904 | Multiple Myelom... Leukemia, Plasm... | Carfilzomib Melphalan Filgrastim | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma | NCT04933539 | Multiple Myelom... | Dexamethasone Carfilzomib Daratumumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy | NCT00216697 | Multiple Myelom... | bortezomib | 20 Years - 74 Years | Janssen Pharmaceutical K.K. | |
| Quality of Life in Multiple Myeloma Patients Treated With Bortezomib | NCT01021592 | Multiple Myelom... | bortezomib | 18 Years - | Janssen Korea, Ltd., Korea | |
| ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. | NCT00440479 | Multiple Myelom... Hematological N... | Bortezomib | 18 Years - | Janssen-Cilag B.V. | |
| A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients | NCT00752518 | Refractory Multiple Myelom... Relapse | bortezomib | 20 Years - 75 Years | Janssen Pharmaceutical K.K. | |
| Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma | NCT03727841 | Anaplastic Epen... Ependymoma Ependymomas | Marizomib | - | National Institutes of Health Clinical Center (CC) | |
| A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | NCT00923247 | Medullary Thyro... | Bortezomib Vandetanib | 18 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. | NCT01026701 | Multiple Myelom... | bortezomib | 18 Years - | Janssen Korea, Ltd., Korea | |
| Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma | NCT01881789 | Multiple Myelom... | Oprozomib Lenalidomide Dexamethasone Cyclophosphamid... | 18 Years - | Amgen | |
| Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma | NCT04933539 | Multiple Myelom... | Dexamethasone Carfilzomib Daratumumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant | NCT05271630 | Multiple Myelom... | Autologous Stem... Immunomodulator... Proteasome Inhi... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands | NCT00440765 | Multiple Myelom... Hematological N... | bortezomib | 18 Years - | Janssen-Cilag B.V. | |
| Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma | NCT01572480 | Multiple Myelom... | Carfilzomib Revlimid Dexamethasone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | NCT04096066 | Multiple Myelom... New Diagnosis T... | Carfilzomib Lenalidomide Dexamethasone | 65 Years - | Fondazione EMN Italy Onlus | |
| A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma | NCT00416273 | Multiple Myelom... | Bortezomib No intervention | 18 Years - 60 Years | Janssen-Cilag G.m.b.H | |
| Autophagy Induction After Bortezomib for Myeloma | NCT01594242 | Multiple Myelom... | Bortezomib | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma | NCT03422874 | Neoplasms Lymphoma | MLN9708 Nelfinavir | 18 Years - | Dartmouth-Hitchcock Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
